The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 29, Issue 6, 2005, Pages 1021-1028

  Reynolds, Gavin P ^a   Templeman, Lucy A ^a   Zhang, Zhi Jun ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

5 HT2C receptor; Antipsychotic drugs; Pharmacogenetics; Polymorphisms; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; SEROTONIN 2C RECEPTOR;

DNA POLYMORPHISM; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MEDICAL ASSESSMENT; NEUROTRANSMISSION; PHARMACOGENOMICS; PROMOTER REGION; RECEPTOR AFFINITY; RECEPTOR GENE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEROTONIN RELEASE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SUBTHALAMIC NUCLEUS; TANDEM REPEAT; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS; RECEPTOR, SEROTONIN, 5-HT2C;

EID: 23144441853     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.03.019     Document Type: Review

References (56)

1. G.K. Aghajanian, and G.J. Marek Serotonin and hallucinogens Neuropsychopharmacology 21 2 Suppl. 1999 16S 23S
2. D.B. Allison, J.L. Mentore, M. Heo, L.P. Chandler, J.C. Cappelleri, M.C. Infante, and P.J. Weiden Antipsychotic-induced weight gain: a comprehensive research synthesis Am. J. Psychiatry 156 1999 1686 1696
3. M.J. Arranz, J. Munro, J. Birkett, A. Bolonna, D. Mancama, M. Sodhi, K.P. Lesch, J.F. Meyer, P. Sham, D.A. Collier, R.M. Murray, and R.W. Kerwin Pharmacogenetic prediction of clozapine response Lancet 355 2000 1615 1616
4. V.S. Basile, M. Masellis, R.S. McIntyre, H.Y. Meltzer, J.A. Lieberman, and J.L. Kennedy Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle J. Clin. Psychiatry 62 Suppl. 23 2001 45 66
5. V.S. Basile, M. Masellis, V. De Luca, H.Y. Meltzer, and J.L. Kennedy - 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain Lancet 360 2002 1790 1791
6. J.E. Blundell Is there a role for serotonin (5-hydroxytryptamine) in feeding? Int. J. Obes. 1 1977 15 42
7. S.J. Briddon, R.A. Leslie, and J.M. Elliott Comparative desensitization of the human 5-HT2A and 5-HT2C receptors expressed in the human neuroblastoma cell line SH-SY5Y Br. J. Pharmacol. 125 1998 727 734
8. C.M. Burns, H. Chu, S.M. Rueter, L.K. Hutchinson, H. Canton, E. Sanders-Bush, and R.B. Emeson Regulation of serotonin-2C receptor G-protein coupling by RNA editing Nature 387 1997 303 308
9. K. Eberle-Wang, I. Lucki, and M.F. Chesselet A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia Neuroscience 72 1996 117 128
10. V.L. Ellingrod, P.J. Perry, B.C. Lund, K. Bever-Stille, F. Fleming, T.L. Holman, and D. Miller 5HT2A and 5-HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia J. Clin. Psychopharmacol. 22 2002 622 624
11. Y.G. Gelders Thymosthenic agents, a novel approach in the treatment of schizophrenia Br. J. Psychiatry 5 1989 33 36
12. B. Gutierrez, B. Arias, S. Papiol, A. Rosa, and L. Fananas Association study between novel promoter variants at the 5-HT2C receptor gene and human patients with bipolar affective disorder Neurosci. Lett. 309 2001 135 137
13. J. Hietala, M. Koulu, M. Kuoppamaki, J. Lappalainen, and E. Syvalahti Chronic clozapine treatment down-regulates serotonin 5-HT-1c receptors in rat brain Prog. Neuro-Psychopharmacol. Biol. Psychiatry 16 1992 727 732
14. C.J. Hong, C.H. Lin, Y.W.Y. Yu, K.H. Yang, and S.J. Tsai Genetic variants of the serotonin system and weight change during clozapine treatment Pharmacogenetics 11 2001 265 268
15. J. Lappalainen, L. Zhang, M. Dean, M. Oz, N. Ozaki, D.H. Yu, M. Virkkunen, F. Weight, M. Linnoila, and D. Goldman Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2C receptor gene (HTR2C) Genomics 27 1995 274 279
16. J. Lappalainen, J.C. Long, M. Virkkunen, N. Ozaki, D. Goldman, and M. Linnoila HTR2C Cys23Ser polymorphism in relation to CSF monoamine metabolite concentrations and DSM-III-R psychiatric diagnoses Biol. Psychiatry 46 1999 821 826
17. K.U. Lentes, A. Hinney, A. Ziegler, K. Rosenkranz, H. Wurmser, N. Barth, K. Jacob, H. Coners, H. Mayer, K.H. Grzeschik, H. Schafer, H. Remschmidt, K.M. Pirke, and J. Hebebrand Evaluation of a Cys23Ser mutation within the human 5-HT2C receptor gene: no evidence for an association of the mutant allele with obesity or underweight in children, adolescents and young adults Life Sci. 61 1997 PL9 PL16
18. SQ. Luo, and ET. Li Effects of repeated administration of serotonergic agonists on diet selection and body weight in rats Pharmacol. Biochem. Behav. 38 1991 495 500
19. A.K. Malhotra, D. Goldman, N. Ozaki, W. Rooney, A. Clifton, R.W. Buchanan, A. Breier, and D. Pickar Clozapine response and the 5-HT2C Cys23Ser polymorphism NeuroReport 7 1996 2100 2102
20. D. Marazziti, A. Rossi, G. Giannaccini, K.M. Zavaglia, L. Dell'Osso, A. Lucacchini, and G.B. Cassano Distribution and characterization of [3H]mesulergine binding in human brain postmortem Eur. Neuropsychopharmacol. 10 1999 21 26
21. M. Masellis, V. Basile, H.Y. Meltzer, J.A. Lieberman, S. Sevy, F.M. Macciardi, P. Cola, A. Howard, F. Badri, M.M. Nothen, W. Kalow, and J.L. Kennedy Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients Neuropsychopharmacology 19 1998 123 132
22. I. Mata-Pastor, M.J. Arranz-Calderon, M. Beperet-Urmeneta, F. Perez-Nievas, P. Sham, and R. Kerwin Influence of serotonergic transmission on response to olanzapine Actas Esp. Psiquiatr. 30 2002 265 271
23. H.Y. Meltzer, S. Matsubara, and J.C. Lee Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values J. Pharmacol. Exp. Ther. 251 1989 238 246
24. J. Meyer, W. Saam, R. Mossner, O. Cangir, G.R. Ortega, T. Tatschner, P. Riederer, T.F. Wienker, and K.P. Lesch Evolutionary conserved microsatellites in the promoter region of the 5-hydroxytryptamine receptor 2C gene (HTR2C) are not associated with bipolar disorder in females J. Neural Transm. 109 2002 939 946
25. A. Milatovich, C.L. Hsieh, G. Bonaminio, L. Tecott, D. Julius, and U. Francke Serotonin receptor 1c gene assigned to X chromosome in human (band q24) and mouse (bands D-F4) Hum. Mol. Genet. 1 1992 681 684
26. D.D. Miller, V.L. Ellingrod, T.L. Holman, P.F. Buckley, and S. Arndt Clozapine-induced weight gain associated with the 5HT2C receptor - 759C/T polymorphism Am. J. Med. Genetics 133 2004 97 100
27. D.G.C. Owens A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs 1999 Cambridge University Press Cambridge
28. C. Pantelis, G.W. Stuart, H.E. Nelson, T.W. Robbins, and T.R. Barnes Spatial working memory deficits in schizophrenia: relationship with tardive dyskinesia and negative symptoms Am. J. Psychiatry 158 2001 1276 1285
29. D.J. Quested, R. Whale, A.L. Sharpley, C.L. McGavin, N. Crossland, P.J. Harrison, and P.J. Cowen Allelic variation in the 5-HT2C receptor (HTR2C) and functional responses to the 5-HT2C receptor agonist, m-chlorophenylpiperazine Psychopharmacology (Berl) 144 1999 306 307
30. K. Quirk, A. Lawrence, J. Jones, A. Misra, V. Harvey, H. Lamb, D. Revell, R.H. Porter, and A.R. Knight Characterisation of agonist binding on human 5-HT2C receptor isoforms Eur. J. Pharmacol. 419 2001 107 112
31. C. Reavill, A. Kettle, V. Holland, G. Riley, and T.P. Blackburn Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist Br. J. Pharmacol. 126 1999 572 574
32. G.P. Reynolds, Z.J. Zhang, and X.B. Zhang Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism Lancet 359 2002 2086 2087
33. G.P. Reynolds, R.J. Meckin, and X. Zhang The functional - 759C/T polymorphism of the 5-HT2C receptor is unrelated to [3H]mesulergine binding in human brain Br. J. Pharmacol., Proc. Suppl. 2003
34. G.P. Reynolds, Z.J. Zhang, and X.B. Zhang Clozapine-induced weight gain is associated with a polymorphism of the promoter region of the 5-HT2C receptor Am. J. Psychiatry 160 2003 677 679
35. G.P. Reynolds, Z.J. Yao, X.B. Zhang, J. Sun, and Z.J. Zhang Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response Eur. Neuropsychopharmacol. 15 2005 143 151
36. M. Rietschel, D. Naber, R. Fimmers, H.J. Moller, P. Propping, and M.M. Nothen Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor NeuroReport 8 1997 1999 2003
37. P.A. Sargent, A.L. Sharpley, C. Williams, E.M. Goodall, and P.J. Cowen 5-HT2C receptor activation decreases appetite and body weight in obese subjects Psychopharmacology (Berl) 133 1997 309 312
38. R.H. Segman, R.P. Ebstein, U. Heresco-Levy, M. Gorfine, M. Avnon, E. Gur, L. Nemanov, and B. Lerer Schizophrenia, chronic hospitalization and the 5-HT2C receptor gene Psychiatr. Genet. 7 1997 75 78
39. R.H. Segman, U. Heresco-levy, B. Finkel, R. Inbar, T. Neeman, M. Schlafman, A. Dorevitch, A. Yakir, A. Lerner, T. Goltser, A. Shelevoy, and B. Lerer Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2CSer and DRD3Gly alleles to susceptibility Psychopharmacology 152 2000 408 413
40. M.S. Sodhi, M.J. Arranz, D. Curtis, D.M. Ball, P. Sham, G.W. Roberts, J. Price, D.A. Collier, and R.W. Kerwin Association between clozapine response and allelic variation in the 5-HT2C receptor gene NeuroReport 7 1995 169 172
41. M.S. Sodhi, P.W. Burnet, A.J. Makoff, R.W. Kerwin, and P.J. Harrison RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia Mol. Psychiatry 6 2001 373 379
42. H.R. Song, A. Gu, and N.C. Schanen Identification of a new polymorphism in the 3′-untranslated region of the human serotonin receptor 2C (5-HT2C) gene Mol. Genet. Metab. 66 1999 224 227
43. L.A. Templeman, G.P. Reynolds, B. Arranz, and L. San Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis Pharmacogenetics 15 2005 195 200
44. L.H. Tecott, and K. Nonogaki Insights into the Serotonergic regulation of food intake: 5-HT2C receptor mutant mice Prim. Psychiatry 7 2000 69 70
45. L.H. Tecott, L.M. Sun, S.F. Akana, A.M. Strack, D.H. Lowenstein, M.F. Dallman, and D. Julius Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors Nature 374 1995 542 546
46. C. Trichard, M.L. Paillere-Martinot, D. Attar-Levy, C. Recassens, F. Monnet, and J.L. Martinot Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients Am. J. Psychiatry 155 1998 505 508
47. S.J. Tsai, C.J. Hong, Y.W.Y. Yu, and C.H. Lin - 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain Lancet 360 2002 1790
48. D. Van Oekelen, W.H. Luyten, and J.E. Leysen 5-HT2A and 5-HT2C receptors and their atypical regulation properties Life Sci. 72 2003 2429 2449
49. J. Veenstra-VanderWeele, G.M. Anderson, and E.H. Cook Pharmacogenetics and the serotonin system: initial studies and furure directions Eur. J. Pharmacol. 410 2000 165 181
50. Q. Wang, P.J. O'Brien, C.X. Chen, D.S. Cho, J.M. Murray, and K. Nishikura Altered G protein-coupling functions of RNA editing isoform and splicing variant serotonin2C receptors J. Neurochem. 74 2000 1290 1300
51. D.A. Wirshing, B.J. Spellberg, S.M. Erhart, S.R. Marder, and W.C. Wirshing Novel antipsychotics and new onset diabetes Biol. Psychiatry 44 1998 778 783
52. B.C-T. Wu, J.T. Warren, J. Shih, R. Tandon, H. Meltzer, and J.K. Fink Analysis of serotonin 5HT2 and 5HT1A receptor coding sequences in schizophrenia patients and control subjects Schizophr. Res. 15 1995 58
53. E. Xie, L.Y. Zhu, L.Y. Zhao, and L.S. Chang The human serotonin 5-HT2C receptor: complete cDNA, genomic structure, and alternatively spliced variant Genomics 35 1996 551 561
54. H. Youssef, G. Lyster, and F. Youssef Familial psychosis and vulnerability to tardive dyskinesia Int. Clin. Psychopharmacol. 4 1989 323 328
55. X. Yuan, K. Yamada, S. Ishiyama-Shigemoto, W. Koyama, and K. Nonaka Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes Diabetologia 43 2000 373 376
56. Z.J. Zhang, X.B. Zhang, W.W. Sha, and X.B. Zhang Association of a polymorphism of the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia Mol. Psychiatry 7 2002 670 671